Jack Copeland

Jack Greene Copeland (born 1942) is an American cardiothoracic surgeon, who has established procedures in heart transplantation including repeat heart transplantation, the implantation of total artificial hearts (TAH) to bridge the time to heart transplant, innovations in left ventricular assist devices (LVAD) and the technique of "piggybacking" a second heart (heterotopic heart transplant) in a person, while leaving them the original.

In 1985, he performed the first successful implant of the Jarvik 7 artificial heart for the purpose of gaining time until a suitable heart donor could be found. The 25-year-old recipient received the heart transplant within two weeks of the implant and survived more than five years.

Copeland co-founded SynCardia Systems and after being head of the cardiothoracic surgery programme at the University of Arizona Medical Center (UAMC) in Tucson for over thirty years, he moved to the University of California, San Diego in 2010.

He was one of the first presidents of the International Society of Heart and Lung Transplantation (ISHLT), a society he helped co-found and who awarded him its Past Pioneer Award in 2013.

Early life and education

Jack Copeland was born in 1942 in Roanoke, Virginia and is the son of a chemical engineer. before returning to Stanford. At Stanford, he became chief resident of cardiac surgery

He was inspired predominantly by heart surgeons Norman Shumway and Edward Stinson and he learned the technique of endomyocardial biopsy and interpretation of organ rejection grading from cardiothoracic surgeon Philip Caves and pathologist Margaret Billingham.

The University of Arizona hired Copeland in 1977

In 1982 Copeland stated that heart transplants were "no longer consider[ed] … an experiment here. It has become a routine and predictable procedure".

By 1985, at the age 43, when he was head of the Cardiovascular and Thoracic Surgery Section at the University of Arizona College of Medicine in Tucson, his team had performed over sixty such transplants. It was the first time this procedure was performed successfully as a temporary measure to buy time until a matching donor heart could be found.

Prior to the first success, in March 1985, Copeland and his team had emergently implanted the unapproved Phoenix total artificial heart in a critically ill young man. The FDA policy of making exceptions for unapproved devices use in true emergencies followed this case. The Michael Drummond case followed in August 1985. Worsening of Drummond's condition created a desperation for action and the decision to use a TAH. It allowed time to find a matching donor heart. He survived more than five years, having received his heart transplant within two weeks of the implant. His cause of death was lymphoma. Following FDA approval to trial the CardioWest TAH, he published his ten-year trial (1993–2002), assessing the performance of the TAH in just less than 100 people with class IV biventricular heart failure and at risk of imminent death. All included in the trial were eligible for transplant but were waiting for donors. The trial demonstrated better clinical outcomes when the TAH was used to bridge-to-transplant. In 2001, he co-founded SynCardia Systems which acquired CardioWest Technologies. In 2004, the SynCardia heart was granted FDA approval for use as a bridge-to-transplant. It is the only TAH to obtain FDA approval and be commercially available.

Other cardiac surgery In 2000, he performed America's first implant of a paediatric ventricular assist device. In 2010, he and his team also reported their results of using LVADs in infants and children with severe heart failure from dilated cardiomyopathy.

Other procedures he has led include heart valve surgery, cardiac bypass surgery in adults and the repair of congenital heart defects in infants.

Later career

He resigned from the University of Arizona in 2010 after heading its Cardiovascular and Thoracic Surgery Section for over thirty years and subsequently moved to San Diego, where his wife was completing her general surgery training.

First FDA approved total artificial heart On 7 January 2011, during a four-hour operation, Copeland was part of the team that implanted, as a bridge-to-transplant, the world's only FDA-approved total artificial heart (TAH) for temporary use.

Heterotopic heart transplant at California On 13 February 2011, Copeland and his team at the UC San Diego Center for Transplantation, performed the rare "piggyback" heart operation again, resulting in a man having two beating hearts in his chest. Termed a heterotopic heart transplantation, recipient Smith received a donor heart while still keeping his own diseased heart. The alternative option, which would have required two operations, was to offer a Left ventricular assist device (LVAD) as a bridge-to-transplantation.

The procedure involved placing the new donor heart on the right side of Smith's own heart and then surgically joining the left atria of both hearts to each other to allow oxygenated blood to flow direct from Smith's heart to the donor heart. The new heart's better functioning left ventricle then pumped blood into the aorta. The patient's own right heart continued to pump blood through the lungs.

In acknowledgment of his achievements with artificial hearts and heart-assist devices, he received the 2001 Barney Clark Award.

In 2013, he received the ISHLT Past Pioneer Award. and has four children.

Selected publications He has authored over 400 articles and presented nationally and internationally.

. . . . . . . . . . .